To explore the full publication, visit PubMed.
We’re excited to highlight a recent publication in Oncogene, titled “ALDH1A3 is the switch that determines the balance of ALDH+ and CD24-CD44+ cancer stem cells, EMT-MET, and glucose metabolism in breast cancer” (PMID: 39251846).
This study underscores the pivotal role of ALDH1A3 in regulating cancer stem cell plasticity, metabolic processes, and tumor progression in breast cancer. The findings offer critical insights into the potential for dual therapeutic targeting of ALDH1A3 and glycolysis to combat tumor growth and metastasis.
At Theranib Inc., this research reinforces our commitment to advancing ALDH1A3-targeted therapies, including our proprietary inhibitor CLM296, as part of our mission to transform cancer care.